ARCHIMED acquires cell line development pioneer ExcellGene to accelerate expansion into biosimilars and high-performance transfection solutions

Global private equity healthcare specialist ARCHIMED acquires a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting (both in the biologic therapeutics sector), partnering with founders and management, to create a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins, and other advanced therapeutics.

Lenz & Staehelin advised ARCHIMED on this transaction. The team was led by Andreas Rötheli and Federico Trabaldo Togna (both Corporate and M&A) and further included Ipek Yüce, Youniss Mussa, Alissa Fourati and Charles Beltjens (all Corporate and M&A), Floran Ponce, Kimberly Hundt and Victoria Kinson (all Tax), as well as Sevan Antreasyan, Anne-Laure Laplace and Gabriel Chaix (all IP and Regulatory).